BRPI0511261A - linhagem isolada de lactobacillus sp., uso de uma linhagem isolada de lactobacillus sp., e composição farmacêutica - Google Patents

linhagem isolada de lactobacillus sp., uso de uma linhagem isolada de lactobacillus sp., e composição farmacêutica

Info

Publication number
BRPI0511261A
BRPI0511261A BRPI0511261-3A BRPI0511261A BRPI0511261A BR PI0511261 A BRPI0511261 A BR PI0511261A BR PI0511261 A BRPI0511261 A BR PI0511261A BR PI0511261 A BRPI0511261 A BR PI0511261A
Authority
BR
Brazil
Prior art keywords
lactobacillus
strain
thymidine
isolated lactobacillus
pharmaceutical composition
Prior art date
Application number
BRPI0511261-3A
Other languages
English (en)
Inventor
Lothar Steidler
Sabine Neirynck
Original Assignee
Vib Vzw
Univ Gent
Univ Cork
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw, Univ Gent, Univ Cork filed Critical Vib Vzw
Publication of BRPI0511261A publication Critical patent/BRPI0511261A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LINHAGEM ISOLADA DE LACTOBACILLUS SP., USO DE UMA LINHAGEM ISOLADA DE LACTOBACILLUS SP., E COMPOSIçãO FARMACêUTICA. A invenção está relacionada a uma linhagem Lactobacillus recombinante, com limitado crescimento e viabilidade no ambiente. Mais particularmente, ela está relacionada a um Lactobacillus recombinante que pode apenas sobreviver em um meio, onde timidina está presente. Por meio dessa estrita dependência da ação da timidina, a morte por falta da timidina é rapidamente induzida nessa linhagem recombinante. Uma modalidade preferida é um Lactobacillus que pode apenas sobreviver em um organismo hospedeiro, onde timidina está presente, mas não pode sobreviver fora do organismo hospedeiro em ausência desse composto meio. Além disso, a referida linhagem Lactobacillus pode ser transformada com moléculas profiláticas e/ou terapêuticas e pode, como tal, ser usada para tratar doenças tais como, mas não limitado a, doenças inflamatórias dos intestinos.
BRPI0511261-3A 2004-05-18 2005-05-18 linhagem isolada de lactobacillus sp., uso de uma linhagem isolada de lactobacillus sp., e composição farmacêutica BRPI0511261A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04102202 2004-05-18
PCT/EP2005/052296 WO2005111194A1 (en) 2004-05-18 2005-05-18 Self-containing lactobacillus strain

Publications (1)

Publication Number Publication Date
BRPI0511261A true BRPI0511261A (pt) 2007-11-27

Family

ID=34929115

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511261-3A BRPI0511261A (pt) 2004-05-18 2005-05-18 linhagem isolada de lactobacillus sp., uso de uma linhagem isolada de lactobacillus sp., e composição farmacêutica

Country Status (9)

Country Link
US (1) US20080253990A1 (pt)
EP (1) EP1751270A1 (pt)
JP (1) JP2007537741A (pt)
KR (1) KR20070026575A (pt)
CN (1) CN101052705A (pt)
AU (1) AU2005243441A1 (pt)
BR (1) BRPI0511261A (pt)
CA (1) CA2567106A1 (pt)
WO (1) WO2005111194A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734823B2 (en) 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8682619B2 (en) 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8852916B2 (en) 2010-01-22 2014-10-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with microorganisms
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
EP3255149A3 (en) * 2006-05-02 2018-04-18 Intrexon Actobiotics NV Microbial intestinal delivery of obesity related peptides
JP2012504116A (ja) * 2008-09-29 2012-02-16 アクトジェニックス・エヌブイ 粘膜での微生物のコロニー形成の低減
KR101667982B1 (ko) * 2010-01-14 2016-10-20 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 염증성 장 질환（ｉｂｄ） 및 과민성 장 증후군（ｉｂｓ）의 예방 및 치료를 위한 재조합 프로바이오틱 박테리아
CN103917639B (zh) 2011-09-23 2017-09-26 英特瑞克斯顿阿克图比奥帝克斯有限公司 经修饰的革兰氏阳性细菌及其用途
HUE038830T2 (hu) 2011-09-23 2018-11-28 Intrexon Actobiotics Nv Módosított gram-pozitív baktériumok és alkalmazásaik
WO2016124239A1 (en) 2015-02-04 2016-08-11 Aurealis Oy Recombinant probiotic bacteria for use in the treatment of a skin dysfunction
WO2020077010A1 (en) * 2018-10-09 2020-04-16 Second Genome, Inc. Lactococcus lactis expression system for delivering proteins efficacious for the treatment of epithelial barrier function disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003298291A1 (en) * 2002-11-15 2004-06-15 Universiteit Gent Self-containing lactobacillus strain

Also Published As

Publication number Publication date
EP1751270A1 (en) 2007-02-14
US20080253990A1 (en) 2008-10-16
JP2007537741A (ja) 2007-12-27
WO2005111194A1 (en) 2005-11-24
CA2567106A1 (en) 2005-11-24
CN101052705A (zh) 2007-10-10
AU2005243441A1 (en) 2005-11-24
KR20070026575A (ko) 2007-03-08

Similar Documents

Publication Publication Date Title
BR112021022789A2 (pt) Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a
BR112022019492A2 (pt) Inibidores de rip1k
BR112022002991A2 (pt) Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos
MX2020008772A (es) Conjugados de il-15, y sus usos.
UY31073A1 (es) Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap)
ECSP10010735A (es) Compuestos químicos 251
BR112012006144A2 (pt) novas individualidades de heparina e métodos de uso.
ECSP088852A (es) Azolopirimidinas como inhibidores de la actividad canabinoidea 1
MX2012006628A (es) Microorganismos probioticos como agentes activos para mejorar el brillo de la piel.
JO3235B1 (ar) مركبات بيررولوبيريميدين و استعمالاتها
UY31067A1 (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
BRPI0510999A (pt) dispositivo de eletrodesionização e métodos de uso
BR112012027765A2 (pt) métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
UY30918A1 (es) Moduladores de lta4h y sus usos
TNSN08400A1 (en) Organic compounds and their uses
WO2007146730A3 (en) Deacetylase inhibitor therapy
GB2453475A (en) Live vaccine strains of francisella
WO2004046346A3 (en) Self-containing lactobacillus strain
BR112022026908A2 (pt) Inibidores de rip1k
WO2018175749A3 (en) LRP1 BINDING AGENTS AND USES THEREOF
ZA202006077B (en) Human kynureninase enzymes and uses thereof
BR112017002166A2 (pt) terapias antibióticas de peptídeos derivados do búfalo d?água
BRPI0703029A (pt) sistema cirúrgico a laser com funcionalidade de controle remoto

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired